会社概要
- 正式社名: SSH (Hangzhou) Pharmaceutical Co., Ltd.
- 国際名称: 时森海（杭州）医药科技有限公司 (SSH (Hangzhou) Pharmaceutical Co., Ltd.), Hangzhou, Zhejiang, China
- ブランド名 / 商号: SSH Pharm
- 登録国: China
- 住所: ZhejiangHangzhou11/F,Building 16,Phase 3,hangzhou Medical Port,Fucheng RD, Qiantang District，Hangzhou，china.310000 • Zhejiang
Founded in March 2020 as Shisenhai (Hangzhou) Pharmaceutical Technology and rebranded under the SSH trademark in 2021, SSH (Hangzhou) Pharmaceutical obtained its Drug Manufacturing License and MAH qualification in 2023 and launched China's first generic vancomycin hydrochloride capsule (Wan Tuoxin) in July 2024. The company manufactures and exports APIs and finished dosage forms including ceftazidime and avibactam sodium for injection, sodium zirconium cyclosilicate, durlobactam, estetrol (E4), and tolvaptan sodium phosphate, with sodium zirconium cyclosilicate raw material and formulation gaining approval in 2025 alongside the company's first innovative-drug compound patent. Offering CRO, CMO, and CDMO contract services, the company serves customers across North America, Europe, Asia, the Middle East, Africa, and Australasia.
事業活動
医薬用化学品
原薬(API)
賦形剤・添加剤
ATC分類(解剖治療化学分類)
- Western Europe: Austria, Belgium, France
- Northern America: Bermuda, Canada, Greenland, Saint Pierre and Miquelon, United States
- Central America: Belize, Costa Rica, El Salvador, Guatemala, Honduras, Mexico, Nicaragua, Panama
- South America: Argentina, Bolivia, Brazil, Chile, Colombia, Ecuador, Falkland Islands, French Guiana, Guyana, Paraguay, Peru, Suriname, Uruguay, Venezuela
当社の製品・サービス
評価
コメント
コメントはありません。
評価とコメントを残す